84.64
3.38 (4.16%)
AIStockmoo Score
| Value 38% | 0.0 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Return on Capital info | NA |
| Timing 38% | 0.6 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Trading near its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 25% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money | NA |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| Only one pillar has a clear reading, so the score is unchanged. | |
| Not in score | |
| Price is high against its 52-week average. Down over 5 years. info | |
| Trend up on all three terms. Short-term momentum rising. info | |
| Price is near resistance. Levels trending down. info | |
| Final Score | 0.20 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Disc Medicine, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| IRON | - | - | - | 5.19 |
| OPT | 583 M | - | - | 4.31 |
| OCUP | 51 M | - | - | 0.870 |
| CTMX | - | - | - | 1.55 |
| ZYME | - | - | - | 7.29 |
| PBYI | - | - | - | 2.73 |
Select this tab to load the latest available analysis.
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.65% |
| % Held by Institutions | 99.13% |
No data within this time range.
No data within this time range.
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |